Interventional Oncology Devices Market By Product (Tumor Ablation Devices [Radiofrequency Ablation Systems, Microwave Ablation Systems, Cryoablation Systems, Irreversible Electroporation Systems, Histotripsy Systems], Embolization Devices [Bland Embolization Particles, Drug-Eluting Beads, Yttrium-90 Radioembolization Microspheres, Embolization Coils, Liquid and Gel Embolic Agents, Occlusion Balloons], Access and Delivery Devices [Microcatheters, Guidewires, Introducer Sheaths, Access Needles, Procedure-Specific Delivery Kits], Image-Guidance and Treatment-Support Systems [Cone-Beam CT Guidance Software, Ultrasound-Fusion Systems, Navigation Systems, Ablation-Confirmation Software, Dosimetry and Treatment-Planning Systems], Bone and Soft-Tissue Access Devices [Powered Bone-Access Systems, Cement-Delivery Systems]); By Application (Liver Cancer [Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma], Colorectal Liver Metastases, Kidney Cancer, Lung Cancer, Prostate Cancer, Bone Tumors and Metastases, Soft-Tissue Tumors, Neuroendocrine Tumor Liver Metastases, Other Solid Tumors); By End User (Hospitals, Cancer Treatment Centers, Interventional Radiology Departments, Academic Medical Centers, Ambulatory Surgical Centers, Specialty Oncology Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Interventional Oncology Devices Market: Procedure Growth, Reimbursement, and Consumables Reshape Supplier Revenue

The Global Interventional Oncology Devices Market was valued at USD 3.03 billion in 2025 and is projected to reach USD 5.26 billion by 2032, growing at a CAGR of 8.2%, according to Strategic Market Research.

 

The interventional oncology devices market is built around image-guided procedures rather than prescription volume. Hospitals generate device demand when interventional radiologists perform tumor ablation, transarterial chemoembolization, bland embolization, radioembolization, or another localized cancer treatment.

 

Capital systems create the initial sale, while probes, antennas, electrodes, microspheres, microcatheters, guidewires, balloons, and procedure kits generate recurring revenue. Suppliers therefore depend less on cancer incidence alone and more on how many patients reach a qualified center, receive authorization, undergo treatment, and return for repeat procedures.

 

Systemic medicines influence when local treatment is used, but completed procedures remain the main commercial unit. Tumor size, location, organ function, surgical eligibility, imaging capacity, multidisciplinary referral, and reimbursement determine whether a diagnosed patient becomes a device user.

 

Boston Scientific and AngioDynamics Show Where Revenue Is Growing

Public company disclosures provide the clearest measure of commercial activity because most manufacturers report interventional oncology inside broader embolization, therapeutic-device, or peripheral-intervention businesses.

Boston Scientific reported USD 996 million in FY2025 Interventional Oncology and Embolization revenue, including USD 263 million in the fourth quarter. Full-year organic growth reached 12.5%, while fourth-quarter organic growth was 12.2%. The category also contains non-oncology embolization, so the figure should be treated as a supplier benchmark rather than the value of the complete market.

AngioDynamics reported USD 11.8 million in NanoKnife revenue during Q4 FY2026, up 64.5% year over year. Disposable-probe revenue increased 47.0%, while capital-system revenue rose 132.5%. New console placements expand the installed base, and every subsequent procedure pulls through another set of single-use probes.

Merit Medical reported Q1 2026 revenue of USD 381.9 million and acquired View Point Medical for USD 140 million. The acquisition added the OneMark detection-imaging system and tissue-marker portfolio to Merit’s therapeutic-oncology offering. Hospitals increasingly buy access, localization, imaging, and delivery products through the same supplier relationship rather than as separate procedural purchases.

 

Liver-Directed Treatment Provides the Largest Patient Pool

Primary liver cancer and liver-dominant metastatic disease account for the broadest use of ablation, TACE, Y-90 radioembolization, and associated delivery devices. Liver cancer applications are estimated to represent 54.2% of 2025 market revenue, equivalent to approximately USD 1.64 billion, and are projected to expand at a CAGR of 8.3% through 2032.

The United States is expected to record 42,340 new liver and intrahepatic bile-duct cancer cases and 30,980 deaths in 2026. Hepatocellular carcinoma represents the main indication for liver-directed procedures, although only a portion of diagnosed patients qualify for treatment.

Tumor number, lesion size, vascular invasion, extrahepatic spread, liver function, performance status, transplant eligibility, and previous therapy narrow the procedure pool. Some patients receive resection or transplantation. Others move directly to systemic therapy, radiation, surveillance, or supportive care.

Colorectal liver metastases, small renal tumors, medically inoperable lung cancer, localized prostate cancer, bone lesions, and selected soft-tissue tumors broaden device use beyond hepatocellular carcinoma. Each indication represents a defined clinical subgroup rather than the full diagnosed population.

Colorectal liver metastases accounted for an estimated 15.6% market share and USD 0.47 billion in 2025 revenue, with a projected CAGR of 8.1%. Kidney cancer contributed approximately 9.8% and USD 0.30 billion, while lung cancer represented 7.4% and USD 0.22 billion; the two applications are projected to grow at CAGRs of 7.3% and 7.8%, respectively.

Prostate cancer applications represented an estimated 4.5% market share and USD 0.14 billion in 2025 revenue and are projected to grow at a CAGR of 12.5%. Bone and soft-tissue tumor applications accounted for 4.1% and approximately USD 0.12 billion, with a projected CAGR of 7.0%. Other solid-tumor applications represented the remaining 4.4%, equivalent to approximately USD 0.13 billion, and are projected to grow at a CAGR of 6.2%.

 

National Procedure Counts Lag Behind Current Market Activity

A historical Medicare study recorded 10,045 interventional oncology procedures in 2008, equal to 29 treatments per 100,000 beneficiaries, and estimated approximately 26,000 procedures nationally. The study confirms that procedure claims can be translated into device demand, but it predates the wider use of microwave ablation, personalized radioembolization dosimetry, irreversible electroporation, and histotripsy.

Procedure counts also differ from patient counts. One patient may undergo staged TACE, repeat ablation, combination treatment, or salvage therapy, while another diagnosed patient may never enter an interventional pathway.

 

Ablation Devices Gain Share Where Surgery Is Risky or Tissue Preservation Matters

Tumor-ablation products include radiofrequency ablation systems, microwave ablation platforms, cryoablation systems, irreversible electroporation devices, and histotripsy platforms. Generators, consoles, robotic systems, gas-delivery units, imaging components, and planning software create capital revenue. Electrodes, antennas, cryoprobes, IRE probes, and treatment accessories provide recurring sales.

Tumor-ablation devices represented an estimated 33.2% of the market and generated approximately USD 1.01 billion in 2025. The segment is projected to grow at a CAGR of 8.7% through 2032 as hospitals adopt microwave, IRE, histotripsy, and advanced cryoablation platforms.

 

Radiofrequency Ablation Retains a Mature Installed Base

Radiofrequency ablation remains widely used for small liver, kidney, lung, and bone tumors. Hospitals already own many RFA generators, and physicians are familiar with electrode placement and treatment planning. RFA accounted for an estimated 27.3% of tumor-ablation device revenue, equivalent to approximately USD 0.27 billion in 2025, and is projected to expand at a CAGR of 5.2%.

RFA therefore remains strongest in smaller tumors, medically inoperable patients, and cases where preserving healthy tissue is more important than achieving the lowest possible recurrence risk. Larger lesions and difficult percutaneous access create demand for microwave, cryoablation, or surgery.

 

Microwave Ablation Expands Beyond Hepatocellular Carcinoma

Microwave systems use generators, internally cooled antennas, power-distribution units, extension cables, and treatment-planning software. Faster heating and larger ablation zones give MWA an advantage in lesions where RFA may be affected by heat loss near major vessels.

Microwave ablation led the tumor-ablation category with an estimated 34.2% share and approximately USD 0.34 billion in 2025 revenue. MWA systems are projected to grow at a CAGR of 8.8% through 2032 as their use expands across liver, kidney, lung, and metastatic tumors.

Surgery remains the preferred curative approach for operable disease, but comparable survival in carefully selected patients gives MWA a stronger role when resection would remove excessive healthy liver, carry high operative risk, or be declined by the patient.

 

Cryoablation Builds Demand in Soft-Tissue and Bone Tumors

Cryoablation systems combine consoles, argon and helium delivery, temperature sensors, protective-displacement accessories, and single-use cryoprobes. The visible ice-ball boundary helps physicians monitor treatment near nerves, skin, ducts, and other sensitive structures.

Cryoablation represented an estimated 20.4% of tumor-ablation device revenue and approximately USD 0.21 billion in 2025. The subsegment is projected to expand at a CAGR of 7.7%, supported by renal, bone, soft-tissue, lung, and pain-management procedures.

Open surgery for desmoid and musculoskeletal tumors can require extensive tissue removal and may impair function. Cryoablation gives hospitals a less invasive option for patients whose tumors are difficult to remove without damaging surrounding structures.

 

NanoKnife Converts Coverage into Console and Probe Sales

Irreversible electroporation has recorded the clearest recent sales acceleration among proprietary ablation platforms. AngioDynamics reported 64.5% year-over-year NanoKnife growth in Q4 FY2026, supported by higher system placements and probe utilization.

IRE systems accounted for an estimated 11.0% of tumor-ablation revenue and approximately USD 0.11 billion in 2025. The subsegment is projected to grow at a CAGR of 12.2% through 2032 as prostate and liver indications support additional console placements and disposable-probe demand.

NanoKnife uses a capital generator, planning software, electrode probes, connection units, and procedure-specific accessories. Each treatment requires several disposable probes, giving AngioDynamics recurring revenue after the initial system placement.

The FDA-cleared prostate indication also expands demand beyond interventional-radiology departments into urology and focal-therapy centers.

 

Histotripsy Creates a Non-Invasive Capital Category

Histotripsy uses focused ultrasound to mechanically destroy targeted tissue without an inserted thermal-ablation probe. The Edison platform combines robotic treatment delivery, ultrasound imaging, planning software, acoustic energy, and single-patient treatment components.

Histotripsy represented an estimated 7.1% of tumor-ablation device revenue and approximately USD 0.07 billion in 2025. Its smaller starting base and planned expansion into additional treatment centers support a projected CAGR of 15.7% through 2032, the highest among the modeled ablation subsegments.

Hospitals must still build referrals, train treatment teams, allocate room capacity, and secure reimbursement before procedure volume reaches commercial scale. Comparative evidence against surgery, thermal ablation, and radiation will determine whether histotripsy moves beyond early-adopter centers.

 

Embolization Produces the Largest Recurring Product Revenue

Embolization products include bland particles, drug-eluting beads, Y-90 radioactive microspheres, detachable and pushable coils, liquid embolics, gel embolics, occlusion balloons, microcatheters, and case-specific delivery sets.

Image-guided procedures led the product market with an estimated 45.8% share and approximately USD 1.39 billion in 2025 revenue. The segment is projected to expand at a CAGR of 8.1% through 2032 as TACE and Y-90 programs increase recurring demand for particles, microspheres, coils, catheters, and administration sets.

Each procedure consumes new therapeutic material and supporting access devices. Boston Scientific’s USD 996 million Interventional Oncology and Embolization business provides the strongest evidence of the segment’s existing commercial scale.

Boston Scientific competes across Y-90 glass microspheres, embolic particles, coils, microcatheters, and cryoablation. Terumo’s portfolio includes Progreat microcatheters, HydroPearl microspheres, LifePearl drug-loadable beads, AZUR coils, guidewires, and Occlusafe microballoon catheters. Portfolio breadth lets each supplier capture access, navigation, embolic delivery, and flow control within the same treatment session.

TACE devices combine selective catheter delivery, chemotherapy, and arterial occlusion. Product demand includes conventional TACE catheters, drug-eluting beads, temporary embolic materials, selective microcatheters, and flow-control balloons. TACE devices represented an estimated 31.8% of embolization-device revenue, equivalent to approximately USD 0.44 billion in 2025, and are projected to expand at a CAGR of 7.9%.

Radioembolization adds Y-90 microspheres, dose vials, administration sets, dosimetry tools, and radiation-protection equipment. Each patient receives a case-specific dose, keeping supplier revenue closely tied to completed treatments. Radioembolization accounted for an estimated 35.7% of embolization-device revenue and approximately USD 0.50 billion in 2025. The subsegment is projected to grow at a CAGR of 9.6%, supported by label expansion, personalized dosimetry, and greater use in liver-dominant disease.

Other embolization products, including bland particles, coils, liquid and gel embolics, and occlusion balloons, represented the remaining 32.5% of embolization revenue, equivalent to approximately USD 0.45 billion in 2025. These products are projected to grow at a CAGR of 6.4% through 2032.

 

Navigation, Imaging, and Access Products Scale Across Every Modality

Microcatheters, guidewires, introducer sheaths, access needles, powered bone-access systems, cone-beam CT software, ultrasound-fusion platforms, navigation tools, and ablation-confirmation applications support nearly every interventional oncology procedure.

Access and delivery devices represented an estimated 11.5% market share and approximately USD 0.35 billion in 2025 revenue, with a projected CAGR of 6.9%. Image-guidance and treatment-support systems accounted for 7.1% and approximately USD 0.22 billion, while their projected CAGR of 9.2% reflects growing demand for navigation, dosimetry, fusion imaging, and ablation-confirmation software.

Bone and soft-tissue access devices represented the remaining 2.4% of product revenue, equivalent to approximately USD 0.07 billion in 2025, and are projected to grow at a CAGR of 5.8% through 2032.

These products carry lower revenue per unit than Y-90 doses or proprietary probes, but their use is broader and more frequent. Every arterial procedure requires selective navigation. Every ablation case depends on accurate applicator placement and confirmation that the treatment zone covers the tumor and intended margin.

Three-dimensional cone-beam CT, image fusion, and ablation-confirmation software help physicians compare the post-treatment zone with the original lesion. Hospitals are more likely to adopt platforms that reduce repeat procedures, prevent incomplete treatment, and shorten review time.

Merit Medical’s acquisition of View Point Medical reflects the move toward integrated oncology workflows. Tissue localization, procedural imaging, access devices, therapeutic delivery, and post-treatment assessment can increasingly be sold through one account.

 

Therapy and Surgical Pathways Determine Device Selection

Primary liver cancer offers the broadest device pathway. Small localized tumors may be treated with RFA, MWA, cryoablation, IRE, histotripsy, resection, or transplantation. Resection remains preferable for operable patients with adequate liver reserve, while ablation is more attractive when surgery would remove too much healthy tissue or create excessive perioperative risk.

Intermediate or multifocal HCC is more likely to generate TACE, bland embolization, or Y-90 demand. These procedures may control disease, reduce tumor burden, bridge a patient to transplantation, or maintain eligibility while an organ becomes available.

Colorectal liver metastases generate demand for thermal ablation, Y-90 microspheres, and preoperative embolization. Surgery offers the strongest curative opportunity when all visible disease can be removed, but tumor distribution, inadequate future liver remnant, comorbidities, and recurrence exclude many patients.

Lung ablation is used mainly in medically inoperable patients with localized non-small-cell lung cancer or limited pulmonary metastases. Surgical resection remains the reference treatment for operable early-stage disease, while stereotactic radiation remains a major non-surgical competitor.

Bone and soft-tissue interventions use cryoablation, RFA, cement-delivery tools, and powered-access systems. Hospitals select these procedures when pain control, structural stability, tissue preservation, or avoidance of highly morbid surgery outweighs the benefit of open removal.

Prostate IRE competes with prostatectomy, radiation, cryotherapy, focused ultrasound, and active surveillance. Growth depends on finding localized-disease patients who want active treatment while preserving surrounding urinary and sexual-function structures.

 

Drug Combinations Could Change the Number and Timing of TACE Procedures

Systemic medicines increasingly affect embolization demand. In LEAP-012, TACE combined with pembrolizumab and lenvatinib produced median progression-free survival of 14.6 months, compared with 10 months for TACE alone.

EMERALD-1 reported median progression-free survival of 15 months with TACE, durvalumab, and bevacizumab, compared with 8.2 months in the control comparison reported by NCI.

Combination regimens may keep TACE in the treatment pathway for longer, generate repeat catheter sessions, and increase multidisciplinary referrals. Strong systemic control could also delay additional procedures. Liver function, toxicity, payer coverage, guidelines, and local capacity will determine the net effect on device volume.

 

Hospitals Prioritize Reimbursement, Utilization, and Treatment Throughput

The hospital or integrated cancer center is the main buyer. Interventional radiologists influence product selection, while oncology service lines, capital committees, value-analysis teams, procurement departments, radiation-safety units, and payers control adoption.

Hospitals accounted for an estimated 63.8% of 2025 market revenue, equivalent to approximately USD 1.93 billion, and are projected to grow at a CAGR of 7.9%. Dedicated cancer treatment centers represented 18.2% and approximately USD 0.55 billion, with a projected CAGR of 9.1% as specialized liver, prostate, and metastatic-tumor programs expand.

Other end users, including academic medical centers, ambulatory surgical centers, specialty oncology clinics, and independent interventional facilities, accounted for the remaining 18.0%, equivalent to approximately USD 0.55 billion in 2025. These facilities are projected to grow at a combined CAGR of 8.3% through 2032.

Capital systems face long sales cycles because hospitals must confirm referral volume, clinical evidence, room availability, training, reimbursement, and projected utilization. Single-use probes, microspheres, catheters, and procedure kits provide more predictable revenue after a treatment platform becomes established.

Coverage remains inconsistent across indications and payers. Billing codes do not guarantee authorization, and expensive disposable products can be difficult to absorb inside bundled hospital payments.

Suppliers increasingly need reimbursement teams, physician training, payer evidence, and center-development programs in addition to conventional sales representatives.

 

North America Has the Strongest Documented Commercial Activity

North America combines recent FDA decisions, public supplier revenue, Medicare coverage developments, specialist centers, and early adoption of IRE and histotripsy. The region accounted for an estimated 42.6% market share and approximately USD 1.29 billion in 2025 revenue, with a projected CAGR of 7.8%. Available evidence supports describing it as the best-documented commercial region without treating public supplier disclosures as proof of an exact regional share.

Europe has mature interventional-radiology infrastructure but stronger health-technology assessment, hospital-budget controls, and tender pressure. Europe represented an estimated 27.8% of 2025 revenue, equivalent to approximately USD 0.84 billion, and is projected to expand at a CAGR of 7.5%.

Asia-Pacific carries a large liver-cancer burden and established catheter and embolization demand, but reimbursement, specialist access, and premium-device pricing differ sharply by country. Asia-Pacific accounted for an estimated 21.7% market share and approximately USD 0.66 billion in 2025 revenue. Its projected CAGR of 10.2% is the highest among the major regions, supported by expanding treatment capacity in China, Japan, India, South Korea, and Southeast Asia.

Latin America and the Middle East and Africa together represented the remaining 7.9% of market revenue, equivalent to approximately USD 0.24 billion in 2025, and are projected to grow at a combined CAGR of 6.9% through 2032.

Regional growth depends more on qualified treatment centers than on population alone. Y-90 programs require dosimetry and radiation handling. IRE and histotripsy need capital placement and training. Thermal ablation requires imaging capacity, referral networks, and access to repeat procedures.

 

Interventional Oncology Devices Market Outlook

Embolization remains the largest visible supplier business, while proprietary ablation platforms are recording the strongest recent growth. NanoKnife is converting reimbursement progress into console and probe sales. Histotripsy is building a non-invasive capital category. MWA and cryoablation are expanding where surgery is unsuitable or would remove excessive healthy tissue.

Cancer incidence will not determine revenue on its own. Referral into specialist centers, clinical eligibility, repeat-treatment intensity, reimbursement, new organ indications, treatment-room throughput, and utilization per installed system will decide how much of the patient pool becomes commercial demand.

Broad portfolio suppliers can capture more products within each case. Proprietary-platform companies can defend premium pricing where clinical evidence, training, reimbursement, and approved indications restrict substitution. Suppliers that combine imaging, treatment delivery, hospital economics, and recurring consumables will hold the strongest position as interventional oncology moves into more cancer pathways.

 

Interventional Oncology Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.03 Billion
Revenue Forecast in 2032	USD 5.26 Billion
Overall Growth Rate	CAGR of 8.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Tumor Ablation Devices, Embolization Devices, Access and Delivery Devices, Image-Guidance and Treatment-Support Systems, Bone and Soft-Tissue Access Devices
By Tumor Ablation Devices	Radiofrequency Ablation Systems, Microwave Ablation Systems, Cryoablation Systems, Irreversible Electroporation Systems, Histotripsy Systems
By Embolization Devices	Bland Embolization Particles, Drug-Eluting Beads, Yttrium-90 Radioembolization Microspheres, Embolization Coils, Liquid and Gel Embolic Agents, Occlusion Balloons
By Access and Delivery Devices	Microcatheters, Guidewires, Introducer Sheaths, Access Needles, Procedure-Specific Delivery Kits
By Image-Guidance and Treatment-Support Systems	Cone-Beam CT Guidance Software, Ultrasound-Fusion Systems, Navigation Systems, Ablation-Confirmation Software, Dosimetry and Treatment-Planning Systems
By Bone and Soft-Tissue Access Devices	Powered Bone-Access Systems, Cement-Delivery Systems
By Application	Liver Cancer, Colorectal Liver Metastases, Kidney Cancer, Lung Cancer, Prostate Cancer, Bone Tumors and Metastases, Soft-Tissue Tumors, Neuroendocrine Tumor Liver Metastases, Other Solid Tumors
By End User	Hospitals, Cancer Treatment Centers, Interventional Radiology Departments, Academic Medical Centers, Ambulatory Surgical Centers, Specialty Oncology Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising adoption of minimally invasive cancer treatment approaches and image-guided procedures • Increasing demand for precision oncology therapies and localized tumor management solutions • Growing integration of advanced imaging, navigation, and treatment-planning technologies
Customization Option	Available upon request